The World Health Organization's first global guidelines on child and adolescent obesity, issued in October 2026, carry a message that parents, pediatricians and the pharmaceutical industry should take to heart: for young people, medicine should be the last resort, not the first.
The WHO strongly recommends structured diet, physical activity and behavior-change programs as the foundation of treatment. It advises against drug therapy, bariatric surgery or weight-loss devices for children under 10. For adolescents 10 to 19, approved medicines should be considered only after a supervised lifestyle program has fallen short.
These recommendations make sense. As an investor in biopharmaceutical innovation, I believe they strike the right balance between the promise of a new generation of drugs and the risks of putting children on them.
For decades, obesity was among the hardest conditions in medicine to treat. Bariatric surgery is demanding and risky; earlier drugs delivered modest results, and some carried severe adverse events. The therapies developed by Eli Lilly and Novo Nordisk, with Amgen and others close behind, are a genuine breakthrough. They work.
But "they work" is not the same as "they are right for a 12-year-old."
First, we simply do not know what decades of treatment will do. These drugs have been in wide use for only a few years. A child who starts today could take them for 60 years or more; no clinical trial has followed anyone that long.
Second, these are largely designed as chronic therapies. Patients who stop tend to regain the weight. Committing a child to lifelong pharmacological weight management is a profound decision, and it should not be made lightly.
Third, rapid loss followed by regain is itself harmful. Weight cycling — losing, gaining, losing again — is hard on the body's organs, particularly the heart.
And the side effects are real. Today's drugs cause a long list of gastrointestinal problems: nausea, bloating, vomiting, diarrhea, constipation and irregular bowel function, with rarer but serious cases of bowel obstruction and pancreatitis. Many patients also lose lean muscle mass along with fat. And the long-term consequences are still unknown.
None of this means drug therapy has no place in pediatrics. Some obesity is fundamentally a biochemical problem — rare genetic disorders that disrupt the signals regulating hunger. Here, targeted medicine is appropriate: Rhythm Pharmaceuticals, for example, has won approval for a therapy aimed at treating some of these disorders.
But most childhood obesity is not of that kind. It is driven by diet and activity, and the right response is to teach children healthy habits early.
So are GLP-1 drugs off the table for young people? Not entirely. Whether they belong in a teenager's care depends on how severe the obesity is, whether it has a genetic cause, and what longer-term data eventually show. What worries me more is the unsupervised route: with so-called peptides and other questionable products easy to find, kids have more ways than ever to chase weight loss on their own.
We should also be honest about incentives. Drug companies genuinely want to treat disease, but it is a business. Acute treatments are less financially attractive, because patients take them briefly, then discontinue treatment once a goal has been achieved. Profit requires either a very high price or a steady stream of new patients to replace them. Chronic therapy solves that problem; a young patient is, commercially, a customer for life. That doesn't make the industry a villain, but parents and physicians should weigh its enthusiasm accordingly.
Where should innovation go next? Not toward more weight loss; today's drugs already deliver that. Nor toward dosing convenience: we have or will have options for daily, weekly, monthly or quarterly administration. The real frontier is safety. Can newer medicines dramatically reduce the gastrointestinal side effects? And can they prevent the loss of lean muscle? Some researchers are testing drug combinations or new compounds to protect muscle, but doing so without introducing new side effects is hard, and the results are not yet in. The goal is the same weight loss, with similar or fewer side effects, and no muscle loss. A therapy that achieves that would change the conversation, especially for younger patients.
Until then, the WHO has it right. For children, the first prescription should be a healthier plate and more time moving. The pharmacy can wait.
Dr. Craig Gordon is the founder, chief executive officer and chief investment officer of GordonMD Global Investments®.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.